• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAR
Click for more information
3.57% 27.0¢

PARADIGM BIOPHARMACEUTICALS LIMITED.. - Announcements

Market Cap $82.30M  ! watchlist Created with Sketch. Add to my watchlist

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company... Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
PAR Response to ASX Price QueryPRICE SENSITIVE28/03/19
PAR Paradigm (PAR) Updated Investor PresentationPRICE SENSITIVE13/03/19
PAR S&P DJI Announces March 2019 Quarterly RebalancePRICE SENSITIVE08/03/19
PAR Half Yearly Report and AccountsPRICE SENSITIVE21/02/19
PAR PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSESPRICE SENSITIVE14/02/19
PAR Appendix 4C - quarterlyPRICE SENSITIVE31/01/19
PAR PARADIGMS SUPPLEMENTARY PHASE 2B DATAPRICE SENSITIVE20/12/18
PAR PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTSPRICE SENSITIVE18/12/18
PAR PAR REPORTS SUCCESSFUL PHASE 2 CLINICAL TRIALPRICE SENSITIVE18/12/18
PAR Trading HaltPRICE SENSITIVE14/12/18
PAR PARADIGM REPORTS CONSISTENT OA PAIN REDUCTIONPRICE SENSITIVE07/12/18
PAR Paradigm's AGM PresentationPRICE SENSITIVE26/11/18
PAR Paradigm in-licenses treatment for rare joint diseasePRICE SENSITIVE22/11/18
PAR PARADIGM RECEIVES $2.32m R&D TAX INCENTIVE REFUNDPRICE SENSITIVE15/11/18
PAR PAR reports pain reduction in 145 people with osteoarthritisPRICE SENSITIVE07/11/18
PAR Quarterly Report and Appendix 4C - quarterlyPRICE SENSITIVE31/10/18
PAR Paradigm Agreement With USA Past Players NetworkPRICE SENSITIVE25/10/18
PAR Paradigm's Updated Corporate PresentationPRICE SENSITIVE25/10/18
PAR Paradigm Raises A$9 MillionPRICE SENSITIVE25/10/18
PAR Trading HaltPRICE SENSITIVE23/10/18
PAR PAR REPORTS PAIN REDUCTION IN OA PATIENTSPRICE SENSITIVE25/09/18
PAR Phase2a RossRiver Virus Clinical Trial Recruitment FinalisedPRICE SENSITIVE28/08/18
PAR Appendix 4E and 2018 Annual ReportPRICE SENSITIVE24/08/18
PAR PAR ACHIEVES 60 PER CENT REDUCTION IN OSTEOARTHRITIS PAINPRICE SENSITIVE15/08/18
PAR PAR achieves 100 per cent recruitment in Phase 2b OA TrialPRICE SENSITIVE06/08/18
PAR Quarterly Report and Appendix 4C - quarterlyPRICE SENSITIVE27/07/18 download Created with Sketch. 508.08KB
PAR Response to ASX Price QueryPRICE SENSITIVE09/07/18 download Created with Sketch. 436.31KB
PAR PAR - 50% REDUCTION IN OSTEOARTHRITIS PAIN MAINTAINEDPRICE SENSITIVE15/06/18 download Created with Sketch. 127.93KB
PAR Paradigm OA Phase 2b Clinical Trial over 80% RecruitedPRICE SENSITIVE17/05/18
PAR Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
PAR PARADIGMs PHASE 2 CLINICAL DATA UPDATEPRICE SENSITIVE27/03/18
PAR PARADIGM REPORTS OSTEOARTHRITIS PAIN REDUCED BY 50%PRICE SENSITIVE01/03/18
PAR Half Year AccountsPRICE SENSITIVE22/02/18
PAR Quarterly Update and Appendix 4CPRICE SENSITIVE30/01/18
PAR PARs European Patent Granted for Bone Marrow Edema LesionsPRICE SENSITIVE16/01/18
PAR Paradigms Two Arthritis Phase 2 Clinical Trials on SchedulePRICE SENSITIVE23/11/17
PAR Paradigms ACL Phase 2 Clinical Trial SuccessPRICE SENSITIVE14/11/17
PAR PAR Successfully Completes A$5.75m PlacementPRICE SENSITIVE06/11/17
PAR Trading HaltPRICE SENSITIVE02/11/17
PAR Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
PAR First Participant Dosed in PARs Phase 2b OA Clinical TrialPRICE SENSITIVE30/10/17
PAR Response to ASX QueryPRICE SENSITIVE11/10/17
PAR PAR REPORTS PAIN REDUCTION IN 83% OF OSTEOARTHRITIS PATIENTSPRICE SENSITIVE10/10/17
PAR PARs Osteoarthritis Phase 2 Receives Ethics ApprovalPRICE SENSITIVE19/09/17
PAR Paradigm Phase 2 Ross River Virus Clinical Trial UpdatePRICE SENSITIVE14/09/17
PAR A PARADIGM SHIFT IN TREATING OSTEOARTHRITIS PAINPRICE SENSITIVE11/09/17
PAR Appendix 4E and 2017 Annual ReportPRICE SENSITIVE29/08/17
PAR Paradigm (PAR) - First Ross River Trial Participant TreatedPRICE SENSITIVE09/08/17
PAR Appendix 4C - quarterlyPRICE SENSITIVE28/07/17
PAR Paradigm To Commence Phase 2 Ross River Virus Clinical TrialPRICE SENSITIVE10/07/17
PAR Paradigm Enters Heart Failure MarketPRICE SENSITIVE20/06/17
PAR Hay Fever Trial UpdatePRICE SENSITIVE16/06/17
PAR Trading HaltPRICE SENSITIVE15/06/17
PAR Paradigm Receives Ethics Approval for Ross River TrialPRICE SENSITIVE22/05/17
PAR Paradigms preclinical hay fever trial publishedPRICE SENSITIVE16/05/17
PAR Paradigm Government grant for Ross River virus researchPRICE SENSITIVE11/05/17
PAR Paradigm March Quarter Update & Appendix 4CPRICE SENSITIVE28/04/17
PAR Final participant treated in Phase 2 hay fever trialPRICE SENSITIVE23/03/17
PAR Paradigm receives $1.34 million R&D tax incentive rebatePRICE SENSITIVE22/03/17
PAR Paradigm Update Ross River Virus Clinical TrialPRICE SENSITIVE07/03/17
PAR Half Year AccountsPRICE SENSITIVE24/02/17
PAR Quarterly Cashflow ReportPRICE SENSITIVE31/01/17
PAR Recruitment complete in Paradigms hay fever clinical trialPRICE SENSITIVE25/01/17
PAR Paradigm's hay fever clinical trial cleared to commencePRICE SENSITIVE22/11/16
PAR Appendix 4C - September 2016 quarter-PAR.AX PRICE SENSITIVE28/10/16
PAR Paradigms Placement heavily oversubscribed-PAR.AX PRICE SENSITIVE18/10/16
PAR Trading Halt-PAR.AX PRICE SENSITIVE14/10/16
PAR Preclinical study underpins efficacy of Paradigm's RhinosulR-PAR.AX PRICE SENSITIVE16/09/16
PAR Paradigm PPS a potential in the treatment of viral arthritis-PAR.AX PRICE SENSITIVE07/09/16
PAR Preliminary Final Report-PAR.AX PRICE SENSITIVE31/08/16
PAR Paradigm PPS nasal spray to treat Allergic Rhinitis-PAR.AX PRICE SENSITIVE19/08/16
PAR Appendix 4C - quarterly-PAR.AX PRICE SENSITIVE28/07/16
PAR Shareholders Update-PAR.AX PRICE SENSITIVE09/06/16
PAR Appendix 4C - quarterly-PAR.AX PRICE SENSITIVE14/04/16
PAR Paradigm initiates second clinical trial sitePRICE SENSITIVE02/03/16
PAR Half Yearly Report and AccountsPRICE SENSITIVE25/02/16
PAR First Participant treated in Paradigms Clinical TrialPRICE SENSITIVE25/02/16
PAR Paradigm starts Clinical TrialPRICE SENSITIVE23/02/16
PAR Appendix 4C - quarterlyPRICE SENSITIVE27/01/16
PAR European Patent Office Grants PAR Key Respiratory PatentPRICE SENSITIVE15/12/15
PAR Elite Athlete successfully treated with Paradigm's ZilosulPRICE SENSITIVE03/12/15
PAR Paradigm Biopharmaceuticals Receives Ethics ApprovalPRICE SENSITIVE23/11/15
PAR Appendix 4C - quarterlyPRICE SENSITIVE28/10/15
PAR Preliminary Final ReportPRICE SENSITIVE31/08/15
PAR Paradigm Secures Key US PatentPRICE SENSITIVE26/08/15
PAR ASX Admission Market ReleasePRICE SENSITIVE18/08/15
PAR Response to ASX Price Query
28/03/19PRICE SENSITIVE
PAR Paradigm (PAR) Updated Investor Presentation
13/03/19PRICE SENSITIVE
PAR S&P DJI Announces March 2019 Quarterly Rebalance
08/03/19PRICE SENSITIVE
PAR Half Yearly Report and Accounts
21/02/19PRICE SENSITIVE
PAR PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSES
14/02/19PRICE SENSITIVE
PAR Appendix 4C - quarterly
31/01/19PRICE SENSITIVE
PAR PARADIGMS SUPPLEMENTARY PHASE 2B DATA
20/12/18PRICE SENSITIVE
PAR PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTS
18/12/18PRICE SENSITIVE
PAR PAR REPORTS SUCCESSFUL PHASE 2 CLINICAL TRIAL
18/12/18PRICE SENSITIVE
PAR Trading Halt
14/12/18PRICE SENSITIVE
PAR PARADIGM REPORTS CONSISTENT OA PAIN REDUCTION
07/12/18PRICE SENSITIVE
PAR Paradigm's AGM Presentation
26/11/18PRICE SENSITIVE
PAR Paradigm in-licenses treatment for rare joint disease
22/11/18PRICE SENSITIVE
PAR PARADIGM RECEIVES $2.32m R&D TAX INCENTIVE REFUND
15/11/18PRICE SENSITIVE
PAR PAR reports pain reduction in 145 people with osteoarthritis
07/11/18PRICE SENSITIVE
PAR Quarterly Report and Appendix 4C - quarterly
31/10/18PRICE SENSITIVE
PAR Paradigm Agreement With USA Past Players Network
25/10/18PRICE SENSITIVE
PAR Paradigm's Updated Corporate Presentation
25/10/18PRICE SENSITIVE
PAR Paradigm Raises A$9 Million
25/10/18PRICE SENSITIVE
PAR Trading Halt
23/10/18PRICE SENSITIVE
PAR PAR REPORTS PAIN REDUCTION IN OA PATIENTS
25/09/18PRICE SENSITIVE
PAR Phase2a RossRiver Virus Clinical Trial Recruitment Finalised
28/08/18PRICE SENSITIVE
PAR Appendix 4E and 2018 Annual Report
24/08/18PRICE SENSITIVE
PAR PAR ACHIEVES 60 PER CENT REDUCTION IN OSTEOARTHRITIS PAIN
15/08/18PRICE SENSITIVE
PAR PAR achieves 100 per cent recruitment in Phase 2b OA Trial
06/08/18PRICE SENSITIVE
PAR Quarterly Report and Appendix 4C - quarterly
27/07/18PRICE SENSITIVE download Created with Sketch. 508.08KB
PAR Response to ASX Price Query
09/07/18PRICE SENSITIVE download Created with Sketch. 436.31KB
PAR PAR - 50% REDUCTION IN OSTEOARTHRITIS PAIN MAINTAINED
15/06/18PRICE SENSITIVE download Created with Sketch. 127.93KB
PAR Paradigm OA Phase 2b Clinical Trial over 80% Recruited
17/05/18PRICE SENSITIVE
PAR Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
PAR PARADIGMs PHASE 2 CLINICAL DATA UPDATE
27/03/18PRICE SENSITIVE
PAR PARADIGM REPORTS OSTEOARTHRITIS PAIN REDUCED BY 50%
01/03/18PRICE SENSITIVE
PAR Half Year Accounts
22/02/18PRICE SENSITIVE
PAR Quarterly Update and Appendix 4C
30/01/18PRICE SENSITIVE
PAR PARs European Patent Granted for Bone Marrow Edema Lesions
16/01/18PRICE SENSITIVE
PAR Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule
23/11/17PRICE SENSITIVE
PAR Paradigms ACL Phase 2 Clinical Trial Success
14/11/17PRICE SENSITIVE
PAR PAR Successfully Completes A$5.75m Placement
06/11/17PRICE SENSITIVE
PAR Trading Halt
02/11/17PRICE SENSITIVE
PAR Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
PAR First Participant Dosed in PARs Phase 2b OA Clinical Trial
30/10/17PRICE SENSITIVE
PAR Response to ASX Query
11/10/17PRICE SENSITIVE
PAR PAR REPORTS PAIN REDUCTION IN 83% OF OSTEOARTHRITIS PATIENTS
10/10/17PRICE SENSITIVE
PAR PARs Osteoarthritis Phase 2 Receives Ethics Approval
19/09/17PRICE SENSITIVE
PAR Paradigm Phase 2 Ross River Virus Clinical Trial Update
14/09/17PRICE SENSITIVE
PAR A PARADIGM SHIFT IN TREATING OSTEOARTHRITIS PAIN
11/09/17PRICE SENSITIVE
PAR Appendix 4E and 2017 Annual Report
29/08/17PRICE SENSITIVE
PAR Paradigm (PAR) - First Ross River Trial Participant Treated
09/08/17PRICE SENSITIVE
PAR Appendix 4C - quarterly
28/07/17PRICE SENSITIVE
PAR Paradigm To Commence Phase 2 Ross River Virus Clinical Trial
10/07/17PRICE SENSITIVE
PAR Paradigm Enters Heart Failure Market
20/06/17PRICE SENSITIVE
PAR Hay Fever Trial Update
16/06/17PRICE SENSITIVE
PAR Trading Halt
15/06/17PRICE SENSITIVE
PAR Paradigm Receives Ethics Approval for Ross River Trial
22/05/17PRICE SENSITIVE
PAR Paradigms preclinical hay fever trial published
16/05/17PRICE SENSITIVE
PAR Paradigm Government grant for Ross River virus research
11/05/17PRICE SENSITIVE
PAR Paradigm March Quarter Update & Appendix 4C
28/04/17PRICE SENSITIVE
PAR Final participant treated in Phase 2 hay fever trial
23/03/17PRICE SENSITIVE
PAR Paradigm receives $1.34 million R&D tax incentive rebate
22/03/17PRICE SENSITIVE
PAR Paradigm Update Ross River Virus Clinical Trial
07/03/17PRICE SENSITIVE
PAR Half Year Accounts
24/02/17PRICE SENSITIVE
PAR Quarterly Cashflow Report
31/01/17PRICE SENSITIVE
PAR Recruitment complete in Paradigms hay fever clinical trial
25/01/17PRICE SENSITIVE
PAR Paradigm's hay fever clinical trial cleared to commence
22/11/16PRICE SENSITIVE
PAR Appendix 4C - September 2016 quarter-PAR.AX
28/10/16PRICE SENSITIVE
PAR Paradigms Placement heavily oversubscribed-PAR.AX
18/10/16PRICE SENSITIVE
PAR Trading Halt-PAR.AX
14/10/16PRICE SENSITIVE
PAR Preclinical study underpins efficacy of Paradigm's RhinosulR-PAR.AX
16/09/16PRICE SENSITIVE
PAR Paradigm PPS a potential in the treatment of viral arthritis-PAR.AX
07/09/16PRICE SENSITIVE
PAR Preliminary Final Report-PAR.AX
31/08/16PRICE SENSITIVE
PAR Paradigm PPS nasal spray to treat Allergic Rhinitis-PAR.AX
19/08/16PRICE SENSITIVE
PAR Appendix 4C - quarterly-PAR.AX
28/07/16PRICE SENSITIVE
PAR Shareholders Update-PAR.AX
09/06/16PRICE SENSITIVE
PAR Appendix 4C - quarterly-PAR.AX
14/04/16PRICE SENSITIVE
PAR Paradigm initiates second clinical trial site
02/03/16PRICE SENSITIVE
PAR Half Yearly Report and Accounts
25/02/16PRICE SENSITIVE
PAR First Participant treated in Paradigms Clinical Trial
25/02/16PRICE SENSITIVE
PAR Paradigm starts Clinical Trial
23/02/16PRICE SENSITIVE
PAR Appendix 4C - quarterly
27/01/16PRICE SENSITIVE
PAR European Patent Office Grants PAR Key Respiratory Patent
15/12/15PRICE SENSITIVE
PAR Elite Athlete successfully treated with Paradigm's Zilosul
03/12/15PRICE SENSITIVE
PAR Paradigm Biopharmaceuticals Receives Ethics Approval
23/11/15PRICE SENSITIVE
PAR Appendix 4C - quarterly
28/10/15PRICE SENSITIVE
PAR Preliminary Final Report
31/08/15PRICE SENSITIVE
PAR Paradigm Secures Key US Patent
26/08/15PRICE SENSITIVE
PAR ASX Admission Market Release
18/08/15PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
27.0¢ 		Change
-0.010(3.57%) 		Mkt cap ! $82.30M
Open High Low Value Volume
28.0¢ 28.0¢ 26.5¢ $281.4K 1.024M

Buyers (Bids)

No. Vol. Price($)
1 3499 27.0¢
 

Sellers (Offers)

Price($) Vol. No.
28.0¢ 161588 8
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
27.5¢ 		  Change
-0.010 ( 1.79 %)
Open High Low Volume
27.5¢ 27.5¢ 26.5¢ 182425
Last updated 15.58pm 21/11/2024 ?
PAR (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.